British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

Pharmaceutical giant GSK and the University of Oxford have teamed up to make a vaccine that targets cells at the pre-cancerous stage. The university has world-leading expertise in the study of pre ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Teva Pharmaceutical Industries Ltd. ADR-3.78% $21.4B ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

After hours: 7:34:23 p.m. EST ...

At close: January 23 at 4:00:02 PM EST ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

HARRISBURG, Pa. - With immigration policy expected to take a dramatic swing on the federal level with the incoming Trump administration, The Pennsylvania House Democratic Policy Committee held a ...